Interrogation of aberrant tissue for protective TCRs
Research type
Research Study
Full title
Interrogation of aberrant tissue from cancer patients and survivors toward the identification of protective TCRs.
IRAS ID
339730
Contact name
Mathew Jones
Contact email
Sponsor organisation
Etcembly
Duration of Study in the UK
3 years, 8 months, 31 days
Research summary
This study aims to use both healthy and abberant tissues and/or blood collected from individuals living with cancer (including patients undergoing therapy) to determine novel methods with which we might target and kill cancer cells.
As cancer cells, and their associated tumours, commonly display some form of dysregulation of the standard life cycle, they often display abnormal proteins on their surface.
This study will collect both healthy and aberrant tissue and/blood from people living with cancer and interrogate the proteins on the cell surface to identify those that may be shared across multiple tumours. Etcembly will subsequently develop immunotherapies that specifically target cells displaying these shared proteins. Specific killing of only cells that display these cancer-associated proteins allows clinicians to target tumours without inducing the side effects commonly observed in current treatment pathways.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
24/SC/0227
Date of REC Opinion
22 Aug 2024
REC opinion
Further Information Favourable Opinion